Functional and Phenotypic Analysis of Two-Day Monocyte-Derived Dendritic Cells Suitable for Immunotherapy Purposes

Autologous Dendritic Cells in Combination With Chemotherapy Restore Responsiveness of T Cells in Breast Cancer Patients: A Single-Arm Phase I/II Trial

“…Following what has been reported by multiple research groups in the world so far, the use of DCs is a safe immunotherapy system; none of the vaccinated patients presented a moderate or serious adverse event. Notably, we found a mild adverse effect in the majority of patients characterized by a reddening of the DCs inoculation area between doses 5 and 6, possibly due to the presence of IL-12 produced by alpha DCs used in the last doses (30); however, this effect was resolved spontaneously 24-36 h later without requiring treatment. We are currently in the clinical follow-up phase to determine favorable clinical response in patients who received DCs concomitantly with chemotherapy.…”

“…As this is the first clinical study in Colombia with DCs derived from monocytes, we evaluated the safety and immunogenicity of these cells in patients newly diagnosed with infiltrating ductal breast cancer who were treated with NAC for a minimum of three cycles. DCs were derived from autologous monocytes with two previously defined maturation cocktails (14,30,31). The mature DCs were dosed interspersed with the NAC-AC scheme in areas close to the tumor, with the aim that these cells were capable of capturing tumor antigens.…”

Image_1.tif

“…Following what has been reported by multiple research groups in the world so far, the use of DCs is a safe immunotherapy system; none of the vaccinated patients presented a moderate or serious adverse event. Notably, we found a mild adverse effect in the majority of patients characterized by a reddening of the DCs inoculation area between doses 5 and 6, possibly due to the presence of IL-12 produced by alpha DCs used in the last doses (30); however, this effect was resolved spontaneously 24-36 h later without requiring treatment. We are currently in the clinical follow-up phase to determine favorable clinical response in patients who received DCs concomitantly with chemotherapy.…”

“…As this is the first clinical study in Colombia with DCs derived from monocytes, we evaluated the safety and immunogenicity of these cells in patients newly diagnosed with infiltrating ductal breast cancer who were treated with NAC for a minimum of three cycles. DCs were derived from autologous monocytes with two previously defined maturation cocktails (14,30,31). The mature DCs were dosed interspersed with the NAC-AC scheme in areas close to the tumor, with the aim that these cells were capable of capturing tumor antigens.…”

Table_1.xlsx

“…As this is the first clinical study in Colombia with DCs derived from monocytes, we evaluated the safety and immunogenicity of these cells in patients newly diagnosed with infiltrating ductal breast cancer who were treated with NAC for a minimum of three cycles. DCs were derived from autologous monocytes with two previously defined maturation cocktails (14,30,31). The mature DCs were dosed interspersed with the NAC-AC scheme in areas close to the tumor, with the aim that these cells were capable of capturing tumor antigens.…”